The Mystery of Extramitochondrial Proteins Lysine Succinylation

Christos Chinopoulos

Department of Biochemistry and Molecular Biology, Semmelweis University, 1094 Budapest, Hungary; chinopoulos.christos@eok.sote.hu; Tel.: +361-4591500 (ext. 60024); Fax: +361-2670031

Abstract: Lysine succinylation is a post-translational modification which alters protein function in both physiological and pathological processes. Mindful that it requires succinyl-CoA, a metabolite formed within the mitochondrial matrix that cannot permeate the inner mitochondrial membrane, the question arises as to how there can be succinylation of proteins outside mitochondria. The present mini-review examines pathways participating in peroxisomal fatty acid oxidation that lead to succinyl-CoA production, potentially supporting succinylation of extramitochondrial proteins. Furthermore, the influence of the mitochondrial status on cytosolic NAD⁺ availability affecting the activity of cytosolic SIRT5 iso1 and iso4—in turn regulating cytosolic protein lysine succinylations—is presented. Finally, the discovery that glia in the adult human brain lack subunits of both alpha-ketoglutarate dehydrogenase complex and succinate-CoA ligase—thus being unable to produce succinyl-CoA in the matrix—and yet exhibit robust pancellular lysine succinylation, is highlighted.

Keywords: succinyl-CoA; ketoglutarate dehydrogenase complex; post-translational modification; lysine; peroxisomes; fatty acid oxidation

1. Background

Succinylation of lysine residues is a post-translational modification occurring in hundreds of proteins which can happen enzymatically or non-enzymatically [1–7]. In either case, the high-energy metabolite, succinyl-CoA, is required. It is a common misconception that succinyl-CoA is exclusively produced inside the mitochondrial matrix by either (i) α-ketoglutarate dehydrogenase complex (KGDHC) (ii) the reversal of succinate-CoA ligase (SUCL); (iii) the catabolism of valine, isoleucine, methionine, thymine, and odd-number chain fatty acids (and perhaps propionate); or iv) through the reaction catalyzed by 3-oxoacid CoA-transferase 1 (OXCT1), see Figure 1. In fact, succinyl-CoA is also produced within peroxisomes—see Section 4—and there are potential routes through which the peroxisomally-generated succinyl-CoA finds its way to the cytosol (discussed below), unlike mitochondrial-made succinyl-CoA that is trapped in the matrix. The present mini-review focuses exclusively on delineating the extramitochondrial pathways yielding succinyl-CoA; furthermore, since some of those pathways depend on NAD⁺ availability, the connection of cytosolic protein lysine succinylation to mitochondrial status is examined. Finally, the notion that glial cells in the adult human brain are known to lack KGDHC and succinate-CoA ligase subunits in their mitochondria, yet exhibit robust pancellular protein lysine succinylation, is emphasized. For excellent reviews regarding the role and regulation of this post-translational modification, the reader is referred to [8–12].
2. Lysine Succinylation Inside and Outside Mitochondria

Protein lysine succinylation is more prevalent inside than outside mitochondria due to the high-rate generation of succinyl-CoA in the citric acid cycle, and the much greater abundance of coenzyme A (CoASH) and acyl-CoAs in the matrix compared to the cytosol [13–15]. Although succinyl-CoA production has been originally attributed to succinate-CoA ligase reversal, we now know that it is rather due to KGDHC activity during glutamate catabolism. This was recently demonstrated in erythropoiesis [16] and is likely to be the case during most other pathophysiological conditions [17–19]. Indeed, succinate-CoA ligase deficiency leads to hyper-succinylation of proteins [20]. Nonetheless, it is firmly established that lysine succinylation also occurs outside mitochondria [2,20–23]. Furthermore, carnitine palmitoyltransferase (CPT), an enzyme attached to the outer mitochondrial membrane facing the cytosol, exhibits lysine succinyltransferase activity [5]. However, mindful of the impermeability of succinyl-CoA across membranes, and with no known transfer mechanism—unlike other acyl-CoAs [24,25]—the question arises as to how this metabolite gets to the cytosol, and from which pathway(s).

3. Extramitochondrial Sites of Succinyl-CoA Production

According to Metabolic Atlas (https://www.metabolicatlas.org/ (accessed on 20 May 2021)) [26], succinyl-CoA can emerge in the cytosol (including the nucleus) through any of the following three routes, see also Figure 1:

(1) Succinylcarnitine + CoA ⇌ carnitine + succinyl-CoA, mediated by carnitine palmitoyltransferase, [27]. The enzyme exhibits three isoforms with tissue-specific distribution: 1A (liver), B (muscle) or C (brain), all located in the outer mitochondrial membrane [28,29], while the C isoform also present in ER [30]. CoA is available in the cytosol by...
many routes, while succinylcarnitine can be transported from peroxisomes through the carrier SLC25A20. Originally reported as a “mitochondrial carnitine/acylcarnitine carrier protein”, it is now known to reside in peroxisomes as well, see Section 4. Succinylcarnitine can be made in peroxisomes as follows: carnitine + succinyl-CoA $\Leftrightarrow$ succinylcarnitine + CoA through carnitine O-octanoyltransferase (CROT) [31,32], reviewed in [33]. In human peroxisomes, the carnitine required for this reaction may be imported by one of the Organic Cation Transporters (OCTs). Rodent peroxisomes express the OCTN3 (Organic Cation Transporter 3) (SLC22A21) carnitine transporter [34,35]. However, a peroxisomal localization of OCTN3 is not being universally accepted [36]. The multiple routes of succinyl-CoA formation within peroxisomes is addressed in Section 4.

(2) Transport of succinyl-CoA from mitochondria to the cytosol. This is based on a model assumption published in [37] attempting to generate a comprehensive, high-quality genome-scale metabolic reconstruction by Thiele and Palsson, but has never been experimentally verified;

(3) ATP + CoA + succinate $\Rightarrow$ AMP + PPi + succinyl-CoA, potentially mediated by a microsomal dicarboxylyl-CoA synthetase (E.C. 6.2.1.23). In rat liver and kidney (but not muscle), dicarboxylic acids (succinate is a dicarboxylic acid) can be converted into their CoA esters by such an enzyme [38,39]. However, it has also been suggested that the enzyme is not active on short-chain dicarboxylic acids such as succinate, because enzyme activity leaned toward zero by decreasing carbon chain length of the dicarboxylic acid, and with C = 5 it was already minimal [38].

In conclusion, it is the author’s opinion that the only viable route of succinyl-CoA provision to the cytosol is through formation of succinyl-CoA within peroxisomes, followed by its export in the form of succinylcarnitine. Thus, the question arises: how does succinyl-CoA form within peroxisomes?

4. Intraperoxisomal Routes of Succinyl-CoA Production

Evidence for the presence of succinyl-CoA within peroxisomes has been circumstantial for decades, stemming from at least two findings: (i) presence of dicarboxylic acids (including succinate) and 3-oxoadipate (3-ketoadipate) in urine which could be precursors to succinyl-CoA in peroxisomes [40–42]; (ii) expression of ACOT4 (an acyl-CoA thioesterase) in peroxisomes, an enzyme capable of hydrolyzing specifically succinyl-CoA [41,43]. Regarding (i), the presence of dicarboxylic acids in urine was mentioned as early as 1934 [44–48]. Dicarboxylic acids are formed by $\omega$-oxidation of monocarboxylic fatty acids. This occurs by an initial hydroxylation of the $\omega$- or the $\omega$-1 carbon by microsomal CYP4A enzymes [49], followed by further oxidations by alcohol and aldehyde dehydrogenases yielding the dicarboxylic acid [50], a process collectively known as $\omega$-oxidation [51]. On the other hand, $\beta$-oxidation of very long dicarboxylic fatty acids occurs in peroxisomes [27]. Dicarboxylic acids may enter peroxisomes as the CoA ester, followed by chain shortening through peroxisomal $\beta$-oxidation. The individual reactions of the peroxisomal $\beta$-oxidation are catalyzed by different enzymes encoded by distinct genes compared with the mitochondrial $\beta$-oxidation system [52]. Overall, the dicarboxylic acids oxidized in peroxisomes may originate from mitochondrially produced monocarboxylic acids [48,53,54] and/or also very long-chain and long-chain monocarboxylic fatty acids through $\omega$-oxidation [55,56]. Very long-chain and long-chain monocarboxylic fatty acids are mostly of plant origin. Current consensus though is that most of the carboxylic acids are activated to the corresponding CoA ester outside the peroxisome by acyl-CoA synthetases localized in the peroxisomal membrane or in the ER [57]. These acyl-CoA esters are then transported across the peroxisomal membrane via a family of ABC transporters. At least four peroxisomal ABC half-transporters have been identified, as reviewed in [58,59]. Regarding adipic acid, it is found in beets but is also used as a food additive (code named: E355) yielding succinyl-CoA in peroxisomes through adipoyl-CoA, see Figure 1. Finally, regarding 3-keto adipate (3-oxoadipate), although its presence in human urine is well documented [60], the pathway forming it is not yet known. 3-keto adipate may lead to succinyl-
CoA formation in peroxisomes through the concerted action of fatty acid oxidation and peroxisomal 3-ketoacyl-CoA thiolase (ACAA1), see Figure 1.

Regarding (ii), nine functional acyl-CoA thioesterases and acyltransferases have been identified in mice and four in humans [61–66]. Human peroxisomes harbor two acyl-CoA thioesterases, ACOT4 and ACOT8, while mice express four (ACOT3-6) [43,67]. Acyl-CoA thioesterases hydrolyze acyl-CoA to the free fatty acid and CoASH. ACOT4 exhibits selectivity towards succinyl-CoA (Km ≈ 13 μM) and glutaryl-CoA (Km ≈ 37 μM) [41], catalyzing the reaction H2O + succinyl-CoA -> CoA + H+ + succinate. Acyl-CoA thioesterase activity was first identified in the 1950s, where a succinyl-CoA thioesterase (most likely ACOT4) was partially purified from pig heart [68]. The existence of ACOT4 in peroxisomes strongly suggests that succinyl-CoA is formed within peroxisomes.

From the above considerations, it is inferred that succinyl-CoA is formed within peroxisomes from long and very long fatty acids (mostly from plant origin), 3-oxoadipate, and adipic acid through multiple routes. Succinyl-CoA is then transformed to succinylcarnitine (through CROT), and now the need arises to export succinylcarnitine through the peroxisomal membrane. For this, the most likely candidate is the SLC25A20 carrier. There is strong evidence of expression of SLC25A20 in peroxisomal membranes, but this is not unequivocally proven [31,32,69,70]. However, peroxisomes do not harbor metabolic pathways using acetyl-CoA, one of the major end products of fatty acid oxidation; therefore, they rely on mechanisms for exporting such products [59]. The SLC25A20 carrier may fill this niche, and thus become the means for succinylcarnitine export to the cytosol.

5. What Is the Connection between the Mitochondrial Status and Extramitochondrial Proteins Lysine Succinylation?

In [71], the conclusion was reached that the extent of proteins lysine succinylation varies with the metabolic state but does not correlate with the mitochondrial NAD+/NADH ratio. Their experiments unequivocally demonstrated that inhibition of the citric acid cycle or the electron transport chain; the use of uncouplers; or the altering of oxygen partial pressure—all known to impact the NAD+/NADH ratio but in a different manner—exerted various effects on proteins lysine succinylation, hinting at no pattern. However, in that study, they specifically examined the succinylation of lysines in mitochondrial proteins. On the other hand, in [20], the authors showed that mutations in the gene coding of a critical subunit of succinate-CoA ligase causes global protein succinylation, not just those found in mitochondria. The authors postulated that this could be due to secondary deficiency of sirtuin SIRT5 attributed to the depletion of NAD+ levels, similarly described in other diseases encompassing mitochondrial dysfunction [72–74]. In the author’s opinion, the cytosolic isoforms iso1 and/or iso4 of SIRT5 mediate the connection between the mitochondrial metabolic state and cytosolic proteins lysine succinylation. To elaborate on this further: Sirtuins are a group of evolutionary-conserved proteins named after a yeast gene called “Silent mating-type Information Regulation 2” [75]. Mammalian cells express seven sirtuin proteins, denoted as SIRT1-SIRT7 [76]. Sirtuins exhibit partially overlapping, but distinct deacylase activities [77]. SIRT1, SIRT2, and SIRT3 are deacylases; SIRT4, which was originally demonstrated to be an ADP-ribosyltransferase and lipoamidase [78] is a demethylglutarylase, dehydroxymethylglutarylase, and demethylglutaconylase [79]; SIRT5 is a robust desuccinylase [80]; SIRT6 has weak deacylase activity, but more efficient deacylase activity towards long chain fatty acyl groups such as myristoyl- and palmitoyl-groups [77]; SIRT7 also shows desuccinylase activity but due to its location it only acts on histones. It has additionally been shown to act as a long-chain deacylase [81]. Sirtuins not only exhibit distinct deacylase activities, but also different subcellular distribution [82]. SIRT1 and SIRT2 reside predominantly in the cytoplasm and can translocate into the nucleus under certain conditions [83]. SIRT3, SIRT4, and SIRT5 were originally considered as predominantly mitochondrial proteins [82,84–86] but, more recently, SIRT5 isoforms iso1 and iso4 were reported to reside in the cytoplasm [87,88]. SIRT6 and SIRT7 reside in the nucleus [89] and nucleolus [82], respectively.
The localization of SIRT5 iso1 and iso4 in the cytosol may be key to understanding why the mitochondrial state influences the extent of cytosolic proteins lysine succinylation. SIRT5 (and SIRT7) removes succinyl adducts from lysines in the presence of NAD\(^+\) [80,90]; the reaction catalyzed is:

\[
\text{H}_2\text{O} + \text{N6-succinyl-L-lysyl-[protein]} + \text{NAD}^+ \rightarrow \text{O-succinyl-ADP-D-ribose} + \text{L-lysyl-[protein]} + \text{nicotinamide}.
\]

From the reaction shown above, it is immediately apparent that lack of NAD\(^+\) would lead to lack of desuccinylation, and thus protein lysines would remain succinylated. Furthermore, how is the cytosolic NADH/NAD\(^+\) ratio regulated, and what is the connection with mitochondria? In eukaryotic cells, the mitochondrial NAD/NADH ratio is approximately 5–10, while in the cytoplasm it ranges between 100 and 1000 [91–93]. While separate, the cytoplasmic and mitochondrial NAD\(^+\)/NADH pools are connected by either (i) biochemical pathways relying on NAD\(^+\)/NADH and/or (ii) NAD\(^+\) biosynthesis. In mammals, NAD\(^+\) biosynthesis may occur via four different routes: de novo synthesis from tryptophan, synthesis from vitamin B\(_5\), nicotinamide, or conversion of nicotinamide riboside [94]. By definition, NAD\(^+\) biosynthetic pathways take much longer than alterations in NAD\(^+\)/NADH ratios [95]; consequently, they are less likely to play a role in the short run and, thus, are not subject to metabolic alterations as they may rapidly occur. Therefore, in all likelihood, reactions in which NADH/NAD\(^+\) are substrates or products influence SIRT5 iso1 and iso4 activity and are the potential culprits for affecting cytosolic proteins lysine succinylation. According to Metabolic Atlas, NADH/NAD\(^+\) participate in >200 reactions in the cytosol. Of course, not all of them are present in all cells, nor all of them are quantitatively important; furthermore, the expression level of many genes coding for enzymes using NAD\(^+\) and/or NADH as ligands exhibit diurnal rhythms on the day scale and/or respond to fasting or feeding [93]. However, the following three are very high flux enzymes, heavily influencing the cytosolic NADH/NAD\(^+\) ratio as a function of the concentration of the reactants. These are: (i) lactate dehydrogenase (LDH), (ii) glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and (iii) cytosolic malate dehydrogenase (MDH1). To this list, the malate/aspartate shuttle should be added, mediating the transfer of reducing equivalents from the cytosol to mitochondria and vice versa [95]. All of the aforementioned reactions are connected under the following scheme: cells perform glycolysis during which NADH is formed by GAPDH, eventually yielding pyruvate; pyruvate may enter mitochondria under conditions supporting oxidative phosphorylation, otherwise becoming lactate and NAD\(^+\); the latter supporting GAPDH reaction; MDH1 may also support GAPDH by means of providing NAD\(^+\), especially in cells with mitochondrial dysfunction [96]; the malate/aspartate shuttle would be the means of transferring the reducing equivalent of NADH made by GAPDH to mitochondria, for the purpose of its oxidation in the electron transport chain. Evidently, none of the above would occur if mitochondrial dysfunction would lead to either a buildup of matrix reducing equivalents or disfavoring the malate/aspartate shuttle by means of decreasing the mitochondrial membrane potential or altering substrate gradients across the inner mitochondrial membrane. All these would eventually hinder the flow of reducing equivalents from the cytosol to the matrix through the shuttle. Thus, although the metabolic state does not correlate with the lysine succinylation extent of mitochondrial proteins [71], it may well do so with the cytosolic proteins, simply due to a decrease in cytosolic NAD\(^+\) availability, just as suggested in [72–74].
6. Glia in the Adult Human Brain Lack Succinyl-CoA and KGDHC Subunits

It is a textbook definition that under physiological conditions, the citric acid cycle operates in all cells harboring mitochondria; however, in 2015 we reported that glia in the adult human brain lack subunits of succinate-CoA ligase, the citric acid cycle enzyme responsible for performing the reversible conversion of succinyl-CoA and ADP (or GDP) to CoASH, succinate, and ATP (or GTP) [97]. Specifically, it was shown that immunoreactivity of subunit SUCLA2 of succinate-CoA ligase in surgical human cortical tissue samples was present exclusively in neurons [98], while subunit SUCLG2 immunoreactivity was confined to cells outlining the cerebral microvasculature [99], see Figures 2 and 3, respectively. Succinate-CoA ligase is a heterodimeric enzyme, composed of an invariant \( \alpha \) subunit encoded by SUCLG1 and a substrate-specific \( \beta \) subunit, encoded by either SUCLA2 or SUCLG2. This dimer combination results in either an ATP-forming (EC 6.2.1.5) or a GTP-forming SUCL (EC 6.2.1.4). Thus, if both SUCLA2 and SUCLG2 are missing, there cannot be succinate-CoA ligase activity. This would necessitate a bypass of succinate-CoA ligase in order to “close” the citric acid cycle in glial cells, and we proposed that the GABA shunt and/or enzymes participating in ketone body metabolism could substantiate this [99]. However, in 2020, we discovered that glia in the adult human brain also lack KGDHC-specific subunits [100], see Figure 4. This means that the ability of yielding succinyl-CoA within the mitochondrial matrix of glial cells is severely restricted, and if it happens, it would only be due to the GABA shunt [101] and/or enzymes catabolizing ketone bodies [102]. On the other hand, robust protein lysine succinylation was observed in the very same cells (Figure 5). The spatial resolution of immunohistochemistry for succinylated protein lysines is not sufficient for colocalization with mitochondrial markers; it is however, evident that lysine succinylation was labelling the cytosol of glia. The lack of succinate-CoA ligase and KGDHC subunits precluding the possibility of enzymatic activity, and thus formation of succinyl-CoA to an appreciable extent (GABA shunt, along with ketone body metabolism, does not encompass succinyl-CoA while it is on low-flux pathways), raises the question as to how there can be protein lysine succinylation in adult human glia. The answer probably lies in the expression profile of peroxisomal enzymes.
Figure 2. The neuronal localization of SUCLA2 immunoreactivity in the human temporal cortex. (A1): The distribution of SUCLA2-positive cells is similar to that of Nissl-labeled cells (red), both present throughout the temporal cortex. (A2): A higher magnification image reveals that essentially all large Nissl-labeled cells with irregular shape demonstrate SUCLA2 immunolabeling (yellow cells). In contrast, small, intensely labeled round-shape cells do not exhibit SUCLA2 immunoreactivity and remain red (arrowheads). Some blood vessels are labeled green because of the peroxidase activity of the red blood cells present in the vessels in the non-perfused human tissue. (A3): A high-magnification confocal microscopy image demonstrating the punctuate location of SUCLA2 immunoreactivity within the Nissl-labeled neurons whereas small glial cells do not exhibit SUCLA2 immunoreactivity. (B1): The distribution of the glial marker S100 (red) is different from that of SUCLA2-positive cells (green). (B2): A higher magnification image demonstrates lack of colocalization between SUCLA2 and S100. Glial cells labeled with S100 are indicated by arrowheads. (B3): High-magnification confocal picture shows that SUCLA2 and S100 are located in different cell types. Scale bars 200 μm for (A1), 50 μm for (A2), 20 μm for (A3), 500 μm for (B1), 50 μm for (B2), and 20 μm for (B3). (Adapted from [98], by permission).
Figure 3. Immunohistochemistry of SUCLG2 and glial markers in the adult human brain. High magnification confocal images demonstrate that SUCLA2 immunoreactivity (green in (a,b)) is present in neurons but not in Iba1-positive microglia cells (red in (a)) and in oligodendroglial cells labelled with basic myelin protein (red in (b)). In turn, SUCLG2 immunoreactivity (green in (c,d)) does not co-localize with Iba1 (red microglia cells in (c)) and cells labelled with basic myelin protein (red oligodendroglial cells in (d)). The arrowheads in (d) point to red blood cells within vessels labelled non-specifically due to their internal peroxidase content. Scale bar = 20 \( \mu \text{m} \). (Adapted from [99], by permission).
Figure 4. DLST (Dihydrolipoyllysine-residue succinyltransferase, E2 subunit of KGDGC) immunolabeling in the human cerebral cortex in relation to neuronal and glial markers. (A): DLST-immunoreactive (DLST-ir) cells are present in the cerebral cortex, with higher density in the deep layers. (B): DLST (green) and fluorescent Nissl staining (red) show that many cells are double-labeled in the cerebral cortex. Arrows point to double-labeled neurons, while black arrowheads point to single-labeled, DLST-immunonegative cells. Note the dot-like distribution of DLST immunolabeling in the double-labeled neurons. (C): A cerebral cortical section double-labeled with DLST (green) and the established astrocyte marker glial fibrillary acidic protein (GFAP; red) to show the lack of double-labeling, suggesting that GFAP-expressing astrocytes are devoid of DLST. White arrowheads point to single-labeled (DLST-ir) neurons; black arrowheads point to single-labeled (GFAP-ir) astrocytes. Scale bars = 300 μm for (A), and 30 μm for (B,C). (Adapted from [100] under the terms of the Creative Commons CC BY license).
Figure 5. Succinyl-lysine immunolabeling in the human cerebral cortex in relation to neuronal and glial markers. (A): Succinyl-lysine-immunoreactive (SUCCLYS-ir) cells are present in the cerebral cortex, with higher density in the deep layers. (B): Succinyl-lysine (green) and fluorescent Nissl staining (red) show that essentially all cells (both neurons and glia) are double-labeled in the cerebral cortex. Arrows point to some of these double-labeled cells. Note the dot-like distribution of succinyl-lysine immunolabeling in the double-labeled cells. (C): A cerebral cortical section double-labeled with succinyl-lysine (green) and the established astrocyte marker glial fibrillary acidic protein (GFAP; red) to show the double-labeling of astrocytes. White arrowheads point to single-labeled (SUCCLYS-ir) neurons. Scale bars = 300 μm for (A) and 30 μm for (B,C). (Adapted from [100] under the terms of the Creative Commons CC BY license).

7. Glia in the Adult Human Brain Express Enzymes Supporting Peroxisomal Succinyl-CoA Production

The Allen Brain Atlas is an integrated spatio-temporal portal for exploring the human central nervous system [103]. It entails RNA-Seq data from 15,928 intact nuclei of middle temporal gyri derived from frozen human brain specimens collected from eight donors,
Figure 6. RNA-Seq data obtained from the Allen Brain Atlas, looking at the expression of genes (indicated on the left) participating in peroxisomal carnitine shuttle and fatty acid oxidation (beta-, omega-3, and omega-6), as a function of cell types. Glial cell types are indicated by the red dash in the top right corner. Image credit: Allen Institute: https://celltypes.brain-map.org/rnaseq/human (accessed on 25 May 2021).

8. Conclusions

Proteins lysine succinylation depends on the provision of the “activated” molecule, succinyl-CoA. Although this is most likely true, it has not been unequivocally shown that lysine succinylation may also occur from succinate, using energy from another molecule. Thus, unless proven otherwise, it will be assumed that succinyl-CoA is critical and sufficient for this post-translational modification. Extramitochondrial protein lysine succinylation may be possible due to peroxisomal succinyl-CoA production. For this, (i) transport of succinyl-CoA outside peroxisomes (in the form of succinylcarnitine) and (ii) conversion of succinylcarnitine to succinyl-CoA by CPT are required. Therefore, extramitochondrial protein lysine succinylation could be dependent on SLC25A20 (the primary transporter of succinylcarnitine across the peroxisomal membrane) and CPT. Desuccinylation of cytosolic proteins is probably dependent on iso1 and iso4 isoforms of sirtuin SIRT5. Experimental data validating—or refuting—these claims are awaited.

Funding: This work was supported by grants from NKFIH (FKP-61822-64888-EATV, VEKOP 2.3.3-15-2016-00012, 2017-2.3.4-TET-RU-2017-00003, KH129567, and K135027) to CC.

Conflicts of Interest: The author declares no conflict of interest.
References

1. Zhang, Z.; Tan, M.; Xiao, Z.; Dai, L.; Chen, Y.; Zhao, Y. Identification of lysine succinylation as a new post-translational modification. Nat. Chem. Biol. 2010, 7, 58–63, doi:10.1038/nchembio.495.

2. Weinert, B.T.; Schölz, C.; Wagner, S.A.; Isemantavičius, V.; Su, D.; Daniel, J.A.; Choudhary, C. Lysine Succinylation Is a Frequently Occurring Modification in Prokaryotes and Eukaryotes and Extensively Overlaps with Acetylation. Cell Rep. 2013, 4, 842–851, doi:10.1016/j.celrep.2013.07.024.

3. Gibson, G.E.; Xu, H.; Chen, H.-L.; Chen, W.; Denton, T.T.; Zhang, S. Alpha-ketoglutarate dehydrogenase complex-dependent succinylation of proteins in neurons and neuronal cell lines. J. Neurochem. 2015, 134, 86–96, doi:10.1111/jnc.13096.

4. Wang, Y.; Guo, Y.R.; Liu, K.; Peiyi, Y.; Liu, R.; Xia, Y.; Tan, L.; Yang, P.; Lee, J.-H.; Li, X.-J.; et al. KAT2A coupled with the αKGDH complex acts as a histone H3 succinyltransferase. Nat. Cell Biol. 2017, 552, 273–277, doi:10.1038/nature25003.

5. Kurmi, K.; Hitosugi, S.; Wiese, E.K.; Boakye-Agyeman, F.; Gonsalves, W.I.; Lou, Z.; Karnitz, L.M.; Goetz, M.P.; Hitosugi, T. Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity. Cell Rep. 2018, 22, 1365–1373, doi:10.1016/j.celrep.2018.01.030.

6. Wagner, G.R.; Payne, R.M. Widespread and Enzyme-independent Ne-Acetylation and Ne-Succinylation of Proteins in the Chemical Conditions of the Mitochondrial Matrix. J. Biol. Chem. 2013, 288, 29036–29045, doi:10.1074/jbc.m113.486753.

7. Wagner, G.R.; Bhatt, D.P.; O’Connell, T.M.; Thompson, J.W.; Dubois, L.G.; Backos, D.; Yang, H.; Mitchell, G.A.; Ikyayeva, O.R.; Stevens, R.D.; et al. A Class of Reactive Acyl-CoA Species Reveals the Non-enzymatic Origins of Protein Acylation. Cell Metab. 2017, 25, 823–837, doi:10.1016/j.cmet.2017.03.006.

8. Sreedhar, A.; Wiese, E.K.; Hitosugi, T. Enzymatic and metabolic regulation of lysine succinylation. Genes Dis. 2020, 7, 166–171, doi:10.1016/j.gendis.2019.09.011.

9. Yang, Y.; Gibson, G.E. Succinylation Links Metabolism to Protein Functions. Neurochem. Res. 2019, 44, 2346–2359, doi:10.1007/s11064-019-02780-x.

10. Hasan, M.; Khatun, M.S.; Kurata, H. Large-Scale Assessment of Bioinformatics Tools for Lysine Succinylation Sites. Cells 2019, 8, 95, doi:10.3390/cells8020095.

11. Alleyn, M.; Breitzig, M.; Lockey, R.; Koliputi, N. The dawn of succinylation: A posttranslational modification. Am. J. Physiol. Physiol. 2018, 314, C228–C232, doi:10.1152/ajpcell.00148.2017.

12. Verdin, E.; Ott, M. 50 years of protein acetylation: From gene regulation to epigenetics, metabolism and beyond. Nat. Rev. Mol. Cell Biol. 2015, 16, 258–264, doi:10.1038/nrm3931.

13. Horie, S.; Isobe, M.; Suga, T. Changes in CoA Pools in Hepatic Peroxisomes of the Rat, under Various Conditions. J. Biochem. 1986, 99, 1345–1352, doi:10.1093/oxfordjournals.jbchem.a135602.

14. Alexson, S.E.; Nedergaard, J.; Cannon, B. Inhibition of acetyl-carnitine oxidation in rat brown-adipose-tissue mitochondria by erucoyl-carnitine is due to sequestration of CoA. Biochem. Biophys. Acta 1985, 834, 149–158, doi:10.1016/0005-2760(85)90150-x.

15. Alexson, S.; Nedergaard, J.; Cannon, B. Partial protection erucoyl-carnitine inhibition in hamster brown-adipose-tissue mitochondria is due to high CoA levels: A comparison with rat brown-adipose-tissue mitochondria. Comp. Biochem. Physiol. Part B Comp. Biochem. 1986, 83, 191–196, doi:10.1016/0305-0491(86)90352-4.

16. Burch, J.S.; Marcero, J.R.; Maschek, J.A.; Cox, J.E.; Jackson, L.K.; Medlock, A.E.; Phillips, J.D.; Dailey, H.A. Glutamine via α-ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis. Blood 2018, 132, 987–998, doi:10.1182/blood-2018-01-829036.

17. Chinopoulos, C. Which way does the citric acid cycle turn during hypoxia? The critical role of α-ketoglutarate dehydrogenase complex. J. Neurosci. Res. 2013, 91, 1030–1043, doi:10.1002/jnr.23196.

18. Chinopoulos, C.; Gerencser, A.A.; Mandi, M.; Mathe, K.; Töröcsik, B.; Doczi, J.; Turiai, L.; Kiss, G.; Konrád, C.; Vajda, S.; et al. Forward operation of adenine nucleotide translocase during F 0 F 1 -ATPase reversal: Critical role of matrix substrate-level phosphorylation. FASEB J. 2010, 24, 2405–2416, doi:10.1096/fj.09-149888.

19. Chinopoulos, C.; Seyfried, T.N. Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis. ASN Neuro 2018, 10, doi:10.1177/1759091418821861.

20. Gut, P.; Mattilainen, S.; Meyer, J.G.; Pallijaev, P.; Richard, J.; Carroll, C.J.; Euro, L.; Jackson, C.B.; Isohanni, P.; Minassian, B.A.; et al. SUCLA2 mutations cause global protein succinylation contributing to the pathomechanism of a hereditary mitochondrial disease. Nat. Commun. 2020, 11, 1–14, doi:10.1038/s41467-020-19743-4.

21. Wagner, G.R.; Hirschey, M.D. Nonenzymatic Protein Acetylation as a Carbon Stress Regulated by Sirtuin Deacetylases. Mol. Cell 2014, 54, 5–16, doi:10.1016/j.molcel.2014.03.027.

22. Park, J.; Chen, Y.; Tishkoff, D.X.; Peng, C.; Tan, M.; Dai, L.; Xie, Z.; Zhang, Y.; Zwaans, B.M.; Skinner, M.E.; et al. SIRT5-Mediated Lysine Desucinylation Impacts Diverse Metabolic Pathways. Mol. Cell 2013, 50, 919–930, doi:10.1016/j.molcel.2013.06.001.

23. Schötz, C.; Lyon, D.; Refsgaard, J.C.; Jensen, L.J.; Choudhary, C.; Weinert, B.T. Avoiding abundance bias in the functional annotation of posttranslationally modified proteins. Nat. Methods 2015, 12, 1003–1004, doi:10.1038/nmeth.3621.

24. MacDonald, M.J.; Smith, A.D.; Hasan, N.M.; Sabat, G.; Fahien, L.A. Feasibility of Pathways for Transfer of Acyl Groups from Mitochondria to the Cytosol to Form Short Chain Acyl-CoAs in the Pancreatic Beta Cell. J. Biol. Chem. 2007, 282, 30596–30606, doi:10.1074/jbc.m702732200.

25. Wellen, K.E.; Hatzivassiliou, G.; Sachdeva, U.M.; Bui, T.V.; Cross, J.R.; Thompson, C.B. ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation. Science 2009, 324, 1076–1080, doi:10.1126/science.1164097.
26. Robinson, J.L.; Kocabag, P.; Wang, H.; Cholley, P.-E.; Cook, D.; Nilsson, A.; Anton, M.; Ferreira, R.; Domenzain, I.; Billa, V.; et al. An atlas of human metabolism. *Sci. Signal.* 2020, 13, eaa21482, doi:10.1126/scisignal.aaz1482.

27. Ferdinandsusse, S.; Denis, S.; van Roermund, C.W.; Wanders, R.J.; Decroment, G. Identification of the peroxisomal β-oxidation enzymes involved in the degradation of long-chain dicarboxylic acids. *J. Lipid Res.* 2004, 45, 1104–1111, doi:10.1194/jlr.m300512-jlr200.

28. Prip-Buus, C.; Thuiller, L.; Abadi, N.; Prasad, C.; Dilling, L.; Klasing, J.; Demaugre, F.; Greenberg, C.R.; Haworth, J.C.; Driin, V.; et al. Molecular and Enzymatic Characterization of a Unique Carnitine Palmitoyltransferase 1A Mutation in the Hutterite Community. *Mol. Genet. Metab.* 2001, 73, 46–54, doi:10.1006/mgen.2001.3176.

29. Ilijst, L.; Mandel, H.; Oostheim, W.; Ruitter, J.P.; Gutman, A.; Wanders, R.J. Molecular basis of hepatic carnitine palmitoyltransferase I deficiency. *J. Clin. Invest.* 1998, 102, 1031–1032, doi:10.1172/jci9297.

30. Rinaldi, C.; Schmidt, T.; Sitt, A.J.; Johnson, J.O.; Lee, P.R.; Chen, K.-L.; Bott, L.C.; Fadó, R.; Harmison, G.H.; Parodi, S.; et al. Mutation in CPT1CAsociated With Pure Autosomal Dominant Spastic Paraplegia. *JAMA Neurol.* 2015, 72, 561–570, doi:10.1001/jamaneurol.2014.4769.

31. Ferdinandsusse, S.; Mulders, J.; Ilijst, L.; Denis, S.; Decroment, G.; Waterham, H.R.; Wanders, R.J. Molecular Cloning and Expression of Human Carnitine Octanoyltransferase: Evidence for Its Role in the Peroxisomal β-Oxidation of Branched-Chain Fatty Acids. *Biochim. Biophys. Res. Commun.* 1999, 263, 213–218, doi:10.1016/j.bbrc.1999.1340.

32. Westin, M.A.K.; Hunt, M.C.; Alexson, S.E.H. Short- and medium-chain carnitine acyltransferases and acyl-CoA thioesterases in mouse provide complementary systems for transport of β-oxidation products out of peroxisomes. *Cell. Mol. Life Sci.* 2008, 65, 982–990, doi:10.1007/s00018-008-7576-6.

33. Chorny, S.; Ilijst, L.; Van Roermund, C.W.T.; Wanders, R.J.A.; Waterham, H.R. Peroxisomal Metabolite and Cofactor Transport in Humans. *Front. Cell Dev. Biol.* 2021, 8, 613892, doi:10.3389/fcell.2021.613892.

34. Lambonwah, A.-M.; Skaug, J.; Scherer, S.W.; Tein, I. A third human carnitine/organic cation transporter (OCTN3) as a candidate for the 5q31 Crohn’s disease locus (IBD5). *Biochem. Biophys. Res. Commun.* 2003, 301, 98–101, doi:10.1016/s0006-291x(02)02946-7.

35. Januszewicz, E.; Pająk, B.; Gajkowska, B.; Samluk, Ł.; Djavadian, R.L.; Hinton, B.T.; Nalecz, K.A. Organic cation/carnitine transporter OCTN3 is present in astrocytes and is up-regulated by peroxisome proliferators-activator receptor agonist. *Int. J. Biochem. Cell Biol.* 2009, 41, 2599–2609, doi:10.1016/j.biocel.2009.08.020.

36. Van Veldhoven, P.P.; De Schryver, E.; Young, S.G.; Zwijsen, A.; Fransen, M.; Espeel, M.; Baes, M.; Van Ael, E. Slc25a17 Gene Trapped Mice: PMP34 Plays a Role in the Peroxisomal Degradation of Phytic and Pristanic Acid. *Front. Cell Dev. Biol.* 2020, 8, 144, doi:10.3389/fcell.2020.00144.

37. Thiele, I.; Falsson, B. Ô A protocol for generating a high-quality genome-scale metabolic reconstruction. *Nat. Protoc.* 2010, 5, 93–121, doi:10.1038/nprot.2009.203.

38. Vamecq, J.; de Hoffmann, E.; Van Hoof, F. The microsomal dicarboxylyl-CoA synthetase. *Biochem. J.* 1985, 230, 683–693, doi:10.1042/bj2300683.

39. Vamecq, J.; Draye, J.-P. Peroxisomal and Mitochondrial βOxidation of Monocarboxylyl-CoA, ω-Hydroxymonocarboxylyl-CoA and Dicarboxylyl-CoA Esters in Tissues from Untreated and Clofibrate-Treated Rats1. *J. Biochem.* 1989, 106, 216–222, doi:10.1093/oxfordjournals.jbchem.a122835.

40. Jin, Z.; Bian, F.; Tomcik, K.; Kelleher, J.K.; Zhang, G.-F.; Brunengraber, H. Compartmentation of Metabolism of the C12-, C9-, and C5-dicarboxylates in Rat Liver, Investigated by Mass Isotopomer Analysis. *J. Biol. Chem.* 2015, 290, 18671–18677, doi:10.1074/jbc.m115.651737.

41. Westin, M.A.K.; Hunt, M.C.; Alexson, S.E.H. The Identification of a Succiny-CoA Thioesterase Suggests a Novel Pathway for Succinate Production in Peroxisomes. *J. Biol. Chem.* 2005, 280, 38125–38132, doi:10.1074/jbc.m508479200.

42. Bharathi, S.S.; Zhang, Y.; Gong, Z.; Muzumdar, R.; Goetzman, E.S. Role of mitochondrial acyl-CoA dehydrogenases in the metabolism of dicarboxylic fatty acids. *Biochem. Biophys. Res. Commun.* 2020, 527, 162–166, doi:10.1016/j.bbrc.2020.04.105.

43. Hunt, M.C.; Rautanen, A.; Westin, M.A.K.; Svensson, L.T.; Alexson, S.E.H. Analysis of the mouse and human acyl-CoA thioesterase (ACOT) gene clusters shows that convergent, functional evolution results in a reduced number of human peroxisomal ACOTs 1. *FASEB J.* 2006, 20, 1855–1864, doi:10.1096/jf.06-6042com.

44. Verkade, P.E.; Van Der Lee, J. Researches on fat metabolism. II. *Biochem. J.* 1934, 28, 31–40, doi:10.1042/bj0280031.

45. Mortensen, P.B. The possible antiketogenic and gluconeogenic effect of the ω-oxidation of fatty acids in rats. *Biochem. Biophys. Acta 1980*, 620, 177–185, doi:10.1016/0005-2760(80)90199-x.

46. Mortensen, P.B.; Gregersen, N. The biological origin of ketoc dicarboxylic aciduria: II. In vivo and in vitro investigations of the β-oxidation of C8–C16 dicarboxylic acids in unstarved, starved and diabetic rats. *Biochim. Biophys. Acta 1986*, 878, 14–19, doi:10.1016/0005-2760(86)90338-3.

47. Kim, N.; Cha, G.-S.; Nagy, L.D.; Yun, C.-H.; Guengerich, F.P. Kinetic Analysis of Lauric Acid Hydroxylation by Human Cytochrome P450 4A1. *Biochemistry 2014*, 53, 6161–6172, doi:10.1021/bi500710e.

48. Sanders, R.-J.; Ofman, R.; Valianpour, F.; Kemp, S.; Wanders, R.J.A. Evidence for two enzymatic pathways for ω-oxidation of docosanoic acid in rat liver microsomes. *J. Lipid Res.* 2005, 46, 1001–1008, doi:10.1194/jlr.m300510-jlr200.
51. Björkhem, I. On the mechanism of regulation of omega oxidation of fatty acids. *J. Biol. Chem.* 1976, 251, 5259–5266, doi:10.1016/s0021-9928(731355)-1.

52. Wanders, R.J.A.; Waterham, H.R. Biochemistry of Mammalian Peroxisomes Revisited. *Annu. Rev. Biochem.* 2006, 75, 295–332, doi:10.1146/annurev.biochem.74.082803.133329.

53. Mortensen, P.B.; Kolvraa, S.; Gregersen, N.; Rasmussen, K. Cyanide-insensitive and clofibrate enhanced β-oxidation of dodecanedioic acid in rat liver an indication of peroxisomal β-oxidation of N-dicarboxylic acids. *Biochim. Biophys. Acta* 1982, 713, 393–397, doi:10.1016/0005-2760(82)90258-2.

54. Gregersen, N.; Kolvraa, S.; Mortensen, P.B.; Rasmussen, K. C6-C10-Dicarboxylic aciduria: Biochemical considerations in relation to diagnosis of β-oxidation defects. *Scand. J. Clin. Lab. Invest.* 1982, 42, 15–27, doi:10.3109/03655818209168396.

55. Sanders, R.; Ofman, R.; Dacremont, G.; Wanders, R.J.A.; Kemp, S. Characterization of the human ω-oxidation pathway for ω-hydroxy-very-long-chain fatty acids. *FASEB J.* 2008, 22, 2064–2071, doi:10.1096/fj.07-099150.

56. Sanders, R.-J.; Ofman, R.; Duran, M.; Kemp, S.; Wanders, R.J. ω-Oxidation of Very-Long-Chain Fatty Acids in Human Liver Microsomes. *J. Biol. Chem.* 2006, 281, 13180–13187, doi:10.1074/jbc.m15481200.

57. Watkins, P.A. Very-long-chain Acyl-CoA Synthetases. *J. Biol. Chem.* 2008, 283, 1773–1777, doi:10.1074/jbc.r700037200.

58. Kemp, S.; Wanders, R.J.A. X-linked adrenoleukodystrophy: Very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. *Mol. Genet. Metab.* 2007, 90, 268–276, doi:10.1016/j.ymgme.2006.10.001.

59. Visser, W.F.; Van Roermund, C.W.T.; Ijlst, L.; Waterham, H.R.; Wanders, R.J.A. Metabolite transport across the peroxisomal membrane. *Biochem. J.* 2006, 401, 365–375, doi:10.1042/bj20061352.

60. Svensson, J.S.; Sydnes, L.K.; Whist, J.E. Identification of 3-oxodicarboxylic acids in human urine. *J. Chromatogr. B Biomed. Sci. Appl.* 1988, 432, 13–19, doi:10.1016/s0378-4347(00)80628-3.

61. Hunt, M.C.; Alexson, S.E.H. Novel functions of acyl-CoA thioesterases and acyltransferases as auxiliary enzymes in peroxisomal lipid metabolism. *Prog. Lipid Res.* 2008, 47, 405–421, doi:10.1016/j.plipres.2008.05.001.

62. Yamada, J.; Matsumoto, I.; Furuhata, T.; Sakuma, M.; Suga, T. Purification and Properties of Long-Chain Acyl-CoA Hydrolases from the Liver Cytosol of Rats Treated with Peroxisome Proliferator. *Arch. Biochem. Biophys.* 1994, 308, 118–125, doi:10.1006/abbio.1994.1017.

63. Svensson, L.T.; Wilecke, M.; Alexson, S.E.H. Peroxisome Proliferators Differentially Regulate Long-Chain Acyl-CoA Thioesterases in Rat Liver. *JBC J. Biol. Inorg. Chem.* 1995, 230, 813–820, doi:10.1111/j.1432-1033.1995.0813h.x.

64. Svensson, L.T.; Alexson, S.E.; Hiltunen, J.K. Very Long Chain and Long Chain Acyl-CoA Thioesterases in Rat Liver Mitochondria. *J. Biol. Chem.* 1995, 270, 12177–12183, doi:10.1074/jbc.270.20.12177.

65. Hunt, M.C.; Nousiainen, S.E.B.; Huttunen, M.K.; Orl, K.E.; Svensson, L.T.; Alexson, S.E.H. Peroxisome Proliferator-induced Long Chain Acyl-CoA Thioesterases Comprise a Highly Conserved Novel Multi-gene Family Involved in Lipid Metabolism. *J. Biol. Chem.* 1999, 274, 34337–34326, doi:10.1074/jbc.274.48.34317.

66. Westin, M.A.; Alexson, S.E.; Hunt, M.C. Molecular Cloning and Characterization of Two Mouse Peroxisome Proliferator-activated Receptor α (PPARα)-regulated Peroxisomal Acyl-CoA Thioesterases. *J. Biol. Chem.* 2004, 279, 21841–21848, doi:10.1074/jbc.m313863200.

67. Jones, J.M.; Nau, K.; Geraghty, M.T.; Erdmann, R.; Gould, S.J. Identification of Peroxisomal Acyl-CoA Thioesterases in Yeast and Humans. *J. Biol. Chem.* 1999, 274, 9216–9223, doi:10.1074/jbc.274.14.9216.

68. Gergely, J.; Hele, P.; Ramakrishnan, C.V. Succinyl and acetyl coenzyme a deacylases. *J. Biol. Chem.* 1952, 198, 324–334.

69. Van der Leij, F.R.; Huijkman, N.C.; Boomsma, C.; Kuipers, J.R.; Bartelds, B. Genomics of the Human Carnitine Acyltransferase Genes. *Mol. Genet. Metab.* 2000, 71, 139–153, doi:10.1006/mgme.2000.3055.

70. Ramsay, R.R.; Gandour, R.D.; van der Leij, F. Molecular enzymology of carnitine transfer and transport. *Biochim. Biophys. Acta (BBA) Protein Struct. Mol. Enzym.* 2001, 1546, 21–43, doi:10.1016/s0167-4838(01)00147-9.

71. Chen, H.; Xu, H.; Potash, S.; Starkov, A.; Belousov, V.V.; Bilan, D.S.; Denton, T.T.; Gibson, G.E. Mild metabolic perturbations alter succinylation of mitochondrial proteins. *J. Neurosci. Res.* 2017, 95, 2244–2252, doi:10.1002/jnr.24103.

72. Carrico, C.; Meyer, J.G.; He, W.; Gibson, B.W.; Verdin, E. The Mitochondrial Acylome Emerges: Proteomics, Regulation by Sirtuins, and Metabolic and Disease Implications. *Cell Metab.* 2018, 27, 497–512, doi:10.1016/j.cmet.2018.01.016.

73. Khan, N.A.; Auranen, M.; Paetel, I.; Pirinen, E.; Euro, L.; Forstrom, S.; Pasila, L.; Velagapudi, V.; Carroll, C.J.; Auwerx, J.; et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. *EMBO Mol. Med.* 2014, 6, 721–731, doi:10.1002/emmm.201403943.

74. Pirinen, E.; Auranen, M.; Khan, N.A.; Brilhante, V.; Urho, N.; Pessia, A.; Hakkarainen, A.; Kuula, J.; Heinonen, U.; Schmidt, M.S.; et al. Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy. *Cell Metab.* 2020, 31, 1078–1090, doi:10.1016/j.cmet.2020.04.008.

75. Greiss, S.; Gartner, A. Sirtuin/Sir2 phylogeny, evolutionary considerations and structural conservation. *Mol. Cells* 2009, 28, 407–415, doi:10.1007/s10059-009-0169-x.

76. Frye, R.A. Phylogenetic Classification of Prokaryotic and Eukaryotic Sir2-like Proteins. *Biochim. Biophys. Res. Commun.* 2000, 273, 793–798, doi:10.1006/bbrc.2000.3000.

77. Feldman, J.L.; Baeza, J.; Denu, J.M. Activation of the Protein Deacetylase SIRT6 by Long-chain Fatty Acids and Widespread Deacetylation by Mammalian Sirtuins. *J. Biol. Chem.* 2013, 288, 31350–31356, doi:10.1074/jbc.c113.511261.

78. Ahuja, N.; Schwer, B.; Carobbio, S.; Waltregny, D.; North, B.J.; Castronovo, V.; Maechler, P.; Verdin, E. Regulation of Insulin Secretion by SIRT4, a Mitochondrial ADP-ribosyltransferase. *J. Biol. Chem.* 2007, 282, 33583–33592, doi:10.1074/jbc.m705488200.
87.
Matsushita, N.; Yonashiro, R.; Ogata, Y.; Sugiura, A.; Nagashima, S.; Fukuda, T.; Inatome, R.; Yanagi, S. Distinct regulation of Nakamura, Y.; Ogura, M.; Tanaka, D.; Inagaki, N. Localization of mouse mitochondrial SIRT proteins: Shift of SIRT3 to nucleus gamma-hydroxybutyrate through the GABA shunt impair mitochondrial substrate-level phosphorylation.
Ravasz, D.; Kacso, G.; Fodor, V.; Horvath, K.; Adam-Vizi, V.; Chinopoulos, C. Catabolism of GABA, succinic semialdehyde or the Human Mitochondrial Sirtuins Sirt3 and Sirt5.
Schlicker, C.; Gertz, M.; Papatheodorou, P.; Kachholz, B.; Becker, C.F.; Steegborn, C. Substrates and Regulation Mechanisms for the Human Mitochondrial Sirtuins Sirt3 and Sirt5.
Stein, L.R.; Imai, S.-I. The dynamic regulation of NAD metabolism in mitochondria.
Williamson, D.H.; Lund, P.; Krebs, H.A. The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver.
Johnson, J.D.; Mehus, J.G.; Tews, K.; Milavetz, B.I.; Lambeth, D.O. Genetic Evidence for the Expression of ATP- and GTP-specific Succinyl-CoA Synthetases in Multicellular Eucaryotes.
Dobolyi, A.; Ostergaard, E.; Bagó, A.G.; Dóczi, T.; Palkovits, M.; Gál, A.; Molnár, M.J.; Adam-Vizi, V.; Chinopoulos, C. Exclusive neuronal expression of Sirt5 isoforms.
Dobolyi, A.; Bagó, A.G.; Gál, A.; Molnár, M.J.; Palkovits, M.; Adam-Vizi, V.; Chinopoulos, C. Localization of SUCL2 subunits of succinyl CoA ligase within the cerebral cortex suggests the absence of matrix substrate-level phosphorylation in glial cells of the human brain. Bioenerg. Biomembr. 2014, 47, 33–41, doi:10.1016/j.s1086-014-9586-4.
Dobolyi, A.; Bago, A.; Palkovits, M.; Nemeria, N.; Jordan, F.; Dóczi, J.; Ambrus, A.; Adam-Vizi, V.; Chinopoulos, C. Exclusive neuronal detection of KGDHC-specific subunits in the adult human brain cortex despite pancellular protein lysine succinylation. Brain Struct. Funct. 2020, 225, 639–667, doi:10.1007/s00429-020-02026-5.
Ravasz, D.; Kacso, G.; Fodor, V.; Horvath, K.; Adam-Vizi, V.; Chinopoulos, C. Catabolism of GABA, succinic semialdehyde or gamma-hydroxybutyrate through the GABA shunt impair mitochondrial substrate-level phosphorylation. Neurochem. Int. 2017, 109, 41–53, doi:10.1016/j.neuint.2017.03.008.
Tretter, L.; Patocs, A.; Chinopoulos, C. Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. Biochim. Biophys. Acta (BBA) Bioenerg. 2016, 1857, 1086–1101, doi:10.1016/j.bbabio.2016.03.012.
Sunkin, S.M.; Ng, L.; Lau, C.; Dolbeare, T.; Gilbert, T.L.; Thompson, C.L.; Hawrylycz, M.; Dang, C. Allen Brain Atlas: An integrated spatio-temporal portal for exploring the central nervous system. Nucleic Acids Res. 2012, 41, D996–D1008, doi:10.1093/nar/gks1042.
Kassmann, C.M. Myelin peroxisomes—Essential organelles for the maintenance of white matter in the nervous system. Biochimie 2014, 98, 111–118, doi:10.1016/j.biochi.2013.09.020.